Medical Devices Enhanced by Microelectronics to Revolutionize the Treatment of Stroke

Franz Bozsak, CEO and co-founder
Stroke can be caused by different clot types and different removal techniques exist.
Removing the clot on the first try

- Improves patient outcome
- Lowers the risk of complications
- Lowers in-hospital cost up to 30%
- Lowers overall cost up to 25%
Sensome's technology to identify clot type

- Array of impedance sensors with incorporated proprietary micro-chip
- AI-powered signal processing algorithm
Low and high frequency currents enable characterization of clot composition
Machine learning algorithm sorts impedance patterns to recognize clots
Micro-electronics technology enables and unmatched miniaturization of our sensor technology
Clotild® SMART STROKE GUIDEWIRE TO DIFFERENTIATE CLOTS

Clotild® is currently not approved anywhere in the world.
Clotild® smart guidewire
crossing a red-blood-cell-rich clot
vs.
crossing a fibrin-rich clot

Clotild® is currently not approved anywhere in the world.

Click above to watch the video!
Sensome's story so far

- **2014**: Sensome founded, team of 4, 200k€ from Concours Mondial d’Innovation
- **2015**: First animal trial and first financing from Business Angels
- **2016**: Change of indication: from heart attack to ischemic stroke
- **2017**: First financing round with VCs (led by Kurma Partners)
- **2018**: World’s firsts: measurement of a human clot and measurement with the World’s smallest impedance meter
- **2019**: International & multi-disciplinary team of 18 people, total financing >9m€ private and 2m€ public funding
smart medical devices to revolutionize tomorrow’s healthcare